PWMG
NBIX icon

Private Wealth Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Private Wealth Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
83
– – ﹤0.01% 486
2026
Q1 		$10.9K Hold
83
– – ﹤0.01% 496
2025
Q4 		$11.8K Sell
83
-3
-3% -$435 ﹤0.01% 466
2025
Q3 		$12.1K Hold
86
– – ﹤0.01% 460
2025
Q2 		$10.8K Buy
86
+58
+207% +$6.65K ﹤0.01% 463
2025
Q1 		$3.1K Sell
28
-58
-67% -$7.35K ﹤0.01% 905
2024
Q4 		$11.7K Buy
86
+59
+219% +$7.3K ﹤0.01% 425
2024
Q3 		$3.11K Sell
27
-44
-62% -$6.03K ﹤0.01% 906
2024
Q2 		$9.78K Buy
71
+44
+163% +$6.03K ﹤0.01% 446
2024
Q1 		$3.72K Hold
27
– – ﹤0.01% 727
2023
Q4 		$3.56K Buy
+27
New +$3.11K ﹤0.01% 745

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Wealth Management Group's NBIX Position: Q2 2026 in Review

Private Wealth Management Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 83 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

Private Wealth Management Group first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Private Wealth Management Group held 83 shares of Neurocrine Biosciences worth $14K as of Q2 2026.
  • Private Wealth Management Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #486 holding.
  • Private Wealth Management Group first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.